Top

08-03-2024 | Crohn's Disease in Pediatrics | Clinical Insights

Adalimumab as a cause of kidney injury in patients with Crohn’s disease

Authors: Krzysztof Skoczyński, Jan Koziej, Sylwia Szymańska, Łukasz Obrycki, Ryszard Grenda, Mieczysław Litwin

Abstract

Introduction

Adalimumab (ADM) is a recombinant human monoclonal antibody (anti-TNFα) used to treat inflammatory bowel diseases. It can cause kidney injury (KI).

Case diagnosis/treatment

We describe two pediatric patients with Crohn’s disease (CD) in whom ADM therapy was associated with kidney injury (KI). The drug was discontinued in both cases. For the first patient, changes were irreversible despite intensive glucocorticosteroid (GCS) therapy. For the second patient, discontinuation of ADM led to an improvement in kidney function.

Conclusions

Due to the risk of KI in patients undergoing ADM therapy, careful assessment of kidney function and early specialist referral are required. Timely withdrawal of ADM can significantly reduce kidney damage, but in some cases, the kidney damage can be irreversible.

Sandys V, Moloney B, Lane L, Qazi J, Doyle B, Barry M, Leavey S, Conlon P (2018) Granulomatous interstitial nephritis secondary to adalimumab therapy. Clin Kidney J 11:219–221. https://doi.org/10.1093/ckj/sfx104CrossRefPubMed

Graziano F, Busè M, Cassata N, Lentini VL, Citrano M (2022) IgA nephropathy in a child: Crohn’s disease-associated or adalimumab induced? Curr Med Res Opin 38:139–143. https://doi.org/10.1080/03007995.2021.2015155CrossRefPubMed

Chen TJ, Yang YF, Huang PH, Lin HH, Huang CC (2010) Permanent renal loss following tumor necrosis factor α antagonists for arthritis. Rheumatol Int 30:1077–1079. https://doi.org/10.1007/s00296-009-1016-2CrossRefPubMed

Usui J, Salvatore SP, Yamagata K, Seshan SV (2023) Clinicopathologic spectrum of renal lesions following anti-TNF-α inhibitor therapy: a single center experience. Kidney360 4:363–373. https://doi.org/10.34067/KID.0000000000000063CrossRef

Tamura H (2023) IgA nephropathy associated with Crohn’s disease. World J Methodol 13:67–78. https://doi.org/10.5662/wjm.v13.i3.67CrossRefPubMedPubMedCentral

Title: Adalimumab as a cause of kidney injury in patients with Crohn’s disease
Authors: Krzysztof Skoczyński
Jan Koziej
Sylwia Szymańska
Łukasz Obrycki
Ryszard Grenda
Mieczysław Litwin
Publication date: 08-03-2024
Publisher: Springer Berlin Heidelberg
Keywords: Crohn's Disease in Pediatrics
Adalimumab
Acute Kidney Injury
Kidney Injury
Crohn's Disease
Pharmacotherapy in Children
Pediatric Nephrology
Published in: Pediatric Nephrology
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-024-06338-0

ACC 2024 Congress

Springer Medicine

Adalimumab as a cause of kidney injury in patients with Crohn’s disease

Abstract

Introduction

Case diagnosis/treatment

Conclusions

ACC 2024 Congress

Springer Medicine

Abstract

Introduction

Case diagnosis/treatment

Conclusions

Please log in to get access to this content